Summary of serious ADRs causing death, necessitating withdrawal or discontinuation of therapy
| ADRs | No. of death | No. of withdrawal or discontinuation * |
| RCTs and prospective cohort studies | ||
| Biliary pseudolithiasis | 0 | 23 |
| Cholelithiasis | 0 | 2 |
| Neutropaenia | 0 | 2 |
| Rash | 0 | 1 |
| Retrospective cohort studies | ||
| Immune haemolytic anaemia | 11 | 30 |
| Leukocytoclastic vasculitis | 0 | 1 |
| X-linked agammaglobulinaemia | 0 | 1 |
| Biliary pseudolithiasis | 0 | 12 |
| Cholelithiasis | 0 | 2 |
| Choledocholithiasis | 0 | 1 |
| Cholestasis | 0 | 1 |
| Hepatic toxicities (liver injury) | 0 | 1 |
| Toxic hepatitis | 0 | 1 |
| Rash | 0 | 3 |
| Anaphylactic | 0 | 3 |
| Vitamin K deficiency | 0 | 1 |
| Non-convulsive status epilepticus | 0 | 1 |
| Total | 11 | 86 |
*When the patients died after withdrawal or discontinuation of ceftriaxone, we counted it both as a case of ‘death’, and as a case of ‘withdrawal or discontinuation’.
ADRs, adverse drug reactions; RCTs, randomised controlled trials.